Shattuck Labs announces public offering of common stock

Shattuck Labs Inc. (NASDAQ: STTK) announced June 9 that it has commenced a public offering of shares of its common stock or pre-funded warrants to purchase shares of its common stock.

The Austin, Texas and Durham, North Carolina-based clinical-stage biotechnology company expects to grant underwriters a 30-day option to purchase up to an additional 15% of the shares at the public offering price, less underwriting discounts and commissions.

The company stated that the proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

Leerink Partners, J.P. Morgan, Piper Sandler and Cantor are acting as joint bookrunning managers for the proposed offering.

A registration statement relating to these securities was filed with the Securities and Exchange Commission on January 13, 2026 and was declared effective on January 21, 2026, according to the company statement.

Shattuck Labs develops monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases. The company's lead program, SL-325, is designed as a DR3 antagonist antibody targeting the DR3/TL1A pathway.

You May Also Be Interested In

• Singularity Future Technology closes $5M registered direct offering
• Aveanna selling stockholders launch 15M share secondary offering
• Elroy Air wins $46M U.S. Army contract for cargo drone system